Sickle Cell Improvement: ENhancing Care in the Emergency Department (SCIENCE)
Sickle Cell Improvement: ENhancing Care in the Emergency Department (SCIENCE)
批准号:
10855133
负责人:
David C Brousseau
金额:
$89.48万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-07-31
关键词:
Abnormal HemoglobinsAccident and Emergency departmentAccountingAcuteAcute PainAdherenceAdoptionAffectAmerican Society of HematologyApplied ResearchBlack raceCaringCategoriesChildChild CareChronicClinicalCollaborationsDataDiscipline of NursingDiseaseDissemination and ImplementationDoseEducationEffectivenessEmergency CareEmergency MedicineEmergency department visitEngineeringErythrocytesFamilyFeedbackFoundationsFundingGoalsGrantGuideline AdherenceGuidelinesHealthHematological DiseaseHospitalizationInheritedInstitutionInterventionInterviewJournalsMedicineModificationNational Heart, Lung, and Blood InstituteNew EnglandOpioidOutcomePainPain managementPathway interactionsPatientsPersonsProtocols documentationQuality of CareQuality of lifeRandomizedReach, Effectiveness, Adoption, Implementation, and MaintenanceRecurrenceRegistriesReportingResearch MethodologySickle CellSickle Cell AnemiaSiteStressStructural RacismStructureTestingTheoretical Domains frameworkTimeUnited StatesUnited States National Academy of SciencesUniversitiesVisitVulnerable PopulationsWashingtonWorkanalytical methodcombatdata toolsdesigneffectiveness/implementation trialevidence baseevidence based guidelinesgroup interventionhospitalization ratesimplementation facilitationimplementation outcomesimplementation researchimplementation scienceimplementation strategyimprovedmultidisciplinarypain scorepediatric emergencysicklingtreatment adherencetreatment guidelinesvaso-occlusive crisisvaso-occlusive pain
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United
States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises
which result in high rates of emergency department visits and hospitalizations, and decreased quality of life.
The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed
pain management guidelines regarding the timeliness of care for children presenting with these acute pain
crises. These evidence based guidelines are infrequently followed, resulting in increased pain and
hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed
as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-
specific pain management protocols to combat structural racism and reduce time to opioid administration.
Our long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive
crisis treated in the emergency department. Our overall aim is to test a care pathway using multifaceted
implementation strategies to increase guideline adherent care for children in the emergency department with
acute painful vaso-occlusive crisis. Our primary aims are: 1) To compare the primary implementation outcomes
of Reach, Adoption, and Implementation for the care pathway for treatment of children with acute painful vaso-
occlusive crisis in the emergency department, between control and intervention groups and 2) To compare the
primary clinical outcomes of guideline adherent care for opioid dose timing, hospitalization rates, and pain
scores for the care pathway for the treatment of children with acute painful vaso-occlusive crises in the
emergency department between control and intervention groups. We will test these aims using a randomized,
multicenter stepped wedge design to conduct a type III hybrid effectiveness-implementation trial of the care
pathway. Our proposal will institute the care pathway across seven emergency departments with the goal of
improving guideline adherent care for children with SCD presenting with an acute pain crisis, thereby improving
pain, decreasing hospitalizations and improving quality of life for this vulnerable population.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Clinical and Translational Science Award
-
批准号:9085610
-
项目类别:
-
资助金额:$42.23万
-
财政年份:2015
-
负责人:David C Brousseau
-
依托单位:
J. NRSA Training Core
-
批准号:10175077
-
项目类别:
-
资助金额:$18.28万
-
财政年份:2015
-
负责人:David C Brousseau
-
依托单位:
Clinical and Translational Science Award
-
批准号:9274055
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:David C Brousseau
-
依托单位:
Clinical and Translational Science Award
-
批准号:9128784
-
项目类别:
-
资助金额:$42.93万
-
财政年份:2015
-
负责人:David C Brousseau
-
依托单位:
The Delaware Comprehensive Sickle Cell Research Center
-
批准号:10463769
-
项目类别:
-
资助金额:$209.27万
-
财政年份:2014
-
负责人:David C Brousseau
-
依托单位:
The Delaware Comprehensive Sickle Cell Research Center
-
批准号:10664915
-
项目类别:
-
资助金额:$209.0万
-
财政年份:2014
-
负责人:David C Brousseau
-
依托单位:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
-
批准号:8528213
-
项目类别:
-
资助金额:$12.16万
-
财政年份:2010
-
负责人:David C Brousseau
-
依托单位:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
-
批准号:7758174
-
项目类别:
-
资助金额:$43.15万
-
财政年份:2010
-
负责人:David C Brousseau
-
依托单位:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
-
批准号:8059606
-
项目类别:
-
资助金额:$54.63万
-
财政年份:2010
-
负责人:David C Brousseau
-
依托单位:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
-
批准号:8225224
-
项目类别:
-
资助金额:$50.5万
-
财政年份:2010
-
负责人:David C Brousseau
-
依托单位:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
-
批准号:8441479
-
项目类别:
-
资助金额:$23.37万
-
财政年份:2010
-
负责人:David C Brousseau
-
依托单位:
Disparities in quality of healthcare affect utilization
-
批准号:7575807
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2006
-
负责人:David C Brousseau
-
依托单位:
Disparities in quality of healthcare affect utilization
-
批准号:7193443
-
项目类别:
-
资助金额:$13.2万
-
财政年份:2006
-
负责人:David C Brousseau
-
依托单位:
Disparities in quality of healthcare affect utilization
-
批准号:7357481
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2006
-
负责人:David C Brousseau
-
依托单位:
Disparities in quality of healthcare affect utilization
-
批准号:7036927
-
项目类别:
-
资助金额:$13.21万
-
财政年份:2006
-
负责人:David C Brousseau
-
依托单位:
Disparities in quality of healthcare affect utilization
-
批准号:7776901
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2006
-
负责人:David C Brousseau
-
依托单位:
SICKLE CELL DISEASE: GENOTYPING CYP2D6 POLYMORPHISMS
-
批准号:7375093
-
项目类别:
-
资助金额:$1.61万
-
财政年份:2005
-
负责人:David C Brousseau
-
依托单位: